Intensive management of hyperglycaemia in acute coronary syndromes. Study design and rationale of the BIOMArCS 2 glucose trial
- 19 September 2011
- journal article
- research article
- Published by Wiley in Diabetic Medicine
- Vol. 28 (10) , 1168-1175
- https://doi.org/10.1111/j.1464-5491.2011.03307.x
Abstract
Elevated admission plasma glucose is associated with increased mortality in patients who are admitted with an acute coronary syndrome. This may be mediated by increased inflammation, apoptosis and coagulation, and by a disturbed endothelial function that can be found in hyperglycaemic patients. Insulin has several characteristics that may potentially counteract these mechanisms. The BIOMArCS programme is a multi-centre initiative and currently consists of three different studies. The effects of acute coronary syndrome on acute biomarkers washout are studied in the BIOMArCS pilot and the value of biomarkers in predicting upcoming acute coronary syndrome events is studied in BIOMArCS 1. The third study (BIOMArCS 2 glucose), which will be presented here, investigates the effectiveness and safety of intensive glucose level control compared with conventional glucose management in patients with acute coronary syndrome and an admission plasma glucose of 7.8-16 mmol/l. In BIOMArCS 2 glucose, a total of 300 patients without insulin-treated diabetes mellitus will be randomized in a 1:1 ratio to either intensive or conventional glucose management on top of standard medical care. The primary endpoint is infarct size as expressed by the cardiac troponin T level 72 h after admission. To study the metabolic effects of insulin administration, we will investigate biomarker washout patterns of various metabolic mechanisms up to 7 days after admission. These markers will address inflammation, oxidative stress, hypercoagulability, endothelial activation and vasodilatation. Current acute coronary syndrome guidelines lack a clear strategy for hyperglycaemia treatment. This study will extend our knowledge on this matter as it may clarify mechanisms and generate hypotheses of if and how myocardial infarct size may be limited by glucose management at admission.Keywords
This publication has 34 references indexed in Scilit:
- Intensive versus Conventional Glucose Control in Critically Ill PatientsNew England Journal of Medicine, 2009
- Management of acute myocardial infarction in patients presenting with persistent ST-segment elevationEuropean Heart Journal, 2008
- Effect of Modified Glucose-Insulin-Potassium on Free Fatty Acids, Matrix Metalloproteinase, and Myoglobin in ST-Elevation Myocardial InfarctionThe American Journal of Cardiology, 2007
- Proinflammatory Effects of Glucose and Anti-Inflammatory Effect of Insulin: Relevance to Cardiovascular DiseaseThe American Journal of Cardiology, 2006
- Cardiac Troponin T at 96 Hours After Acute Myocardial Infarction Correlates With Infarct Size and Cardiac FunctionJournal of the American College of Cardiology, 2006
- U-Shaped Relationship of Blood Glucose With Adverse Outcomes Among Patients With ST-Segment Elevation Myocardial InfarctionJournal of the American College of Cardiology, 2005
- Metabolic SyndromeCirculation, 2005
- Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidityEuropean Heart Journal, 2005
- ST resolution in a single electrocardiographic lead: A simple and accurate predictor of cardiac mortality in patients with fibrinolytic therapy for acute ST-elevation myocardial infarctionAmerican Heart Journal, 2005
- Association between hyperglycemia and the no-reflow phenomenon inpatients with acute myocardial infarctionJournal of the American College of Cardiology, 2002